Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Japan-based Santen Pharmaceutical (Santen) has signed a licensing agreement with Oak Pharmaceuticals, a subsidiary of Akorn, pertaining to the sales and marketing of tafluprost in the US.
Subscribe to our email newsletter
Tafluprost, which is indicated for the treatment of glaucoma and ocular hypertension, is trademarked as Zioptan in the US and as Tapros in Japan.
Oak recently acquired tafluprost business from Merck and has been granted the rights to sell and market the drug in the US by Santen pursuant to the agreement.
Tafluprost is a prostaglandin analogue jointly developed by Santen and Asahi Glass for the treatment of glaucoma and elevated intraocular pressure.
Santen had granted the US licensing rights for tafluprost to Merck in April 2009.
As part of the deal, Santen has certain rights to receive royalties on sales of Zioptan from Oak Pharmaceuticals.
Founded in 1890, Santen is focused in the research, development and marketing of ophthalmic products for physicians worldwide.
Akorn is engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals and it has manufacturing facilities in Decatur, Illinois, Somerset, New Jersey and Paonta Sahib, India where the company manufactures ophthalmic and injectable pharmaceuticals.
Image: Tafluprost is trademarked as Zioptan in the US and as Tapros in Japan. Photo: courtesy of Vichaya Kiatying-Angsulee/ freedigitalphotos.net